Navigation Links
Joyant-Licensed Technology Earns Broad Patent Protection
Date:2/15/2011

DALLAS, Feb 15, 2011 /PRNewswire/ -- Joyant Pharmaceuticals Inc. ("Joyant"), a privately-held pharmaceutical company, announced the grant of an exceptional US patent covering an entire class of anti-cancer therapeutics based upon Smac mimetics.  Smac mimetics represent a novel approach to targeting the apoptotic pathway and have broad potential for the treatment of cancer, both solid tumor and hematological malignancies.

The United States Patent and Trademark Office (USPTO) granted US Pat. No. 7,884,211 on Joyant's exclusively-licensed anticancer drug technology.  "The USPTO issues broad claims like this only for truly pioneering inventions," noted Richard Aron Osman, JD, PhD, of the Science and Technology Law Group, the patent attorney responsible for prosecuting the patent application.

"Smac" is a natural protein that triggers the destruction of cancer cells. Researchers at UT Southwestern Medical Center serendipitously discovered that dimeric small molecule Smac mimics are extremely effective killers of cancer cells.  Joyant Pharmaceuticals, the exclusive licensee of this UT Southwestern technology, is actively developing Smac mimetics as anti-cancer therapeutics.

"We are very pleased with the scope of this issued patent.  It is a testament to the innovation and potential in our Smac mimetic program," said Dr. Lai Wang, Director of Research at Joyant.

"It is one of our most promising development platforms, with outstanding lead compounds."

About Joyant

Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Joyant is actively translating the molecular pathways that control the growth, replication, and apoptosis of human cells into signaling-based targeted therapeutics.  Joyant has the financial backing of Sanderling Ventures.


'/>"/>
SOURCE Joyant Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Proventix Helps Princeton Baptist Medical Center Earn National Recognition from HIMSS/ASQ for Quality Improvement Using Information Technology
2. Reportlinker Adds Global Anti-counterfeit Markets in Food & Pharmaceutical Applications by Geography, Technology Trends and Forecasts (2010-2015)
3. DSM Biologics Reports a New Record Achievement with DSMs Proprietary XD® Process Technology with a CHO Cell Line Producing an Fc-fusion Protein:
4. Abbotts Ibis Technology Identified Fatal Disease Organism in Afghanistan
5. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
6. Endologix Announces Favorable Clinical Results for Nellix Technology
7. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
8. US Army Study Shows STB Lifesaving Technologys® FAST® Dressing Superior to the Most Effective Currently Available Agents for Controlling Arterial Bleeding
9. Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List
10. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
11. Crestwood Technology Group Receives Silver Boeing Performance Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment of ... doses of biotin in progressive multiple sclerosis: extension phase results ... Ayman Tourbah , Principal Investigator of the Phase 3 study, ... (EAN) in Copenhagen, Denmark . The oral ... Sunday, 29 May 2016 from 14:45 to 16:15 CEST in ...
(Date:5/24/2016)... May 24, 2016   ... beide primären Endpunkte und demonstriert Ebenbürtigkeit ... ‚ausgezeichneter plus guter , ... ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... neue positive Daten von der MORA-Studie der Phase ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... Each year Standard Process Inc. ... is this year’s Life University winner of a $2,500 scholarship from ... Leadership Awards ceremony. , Outerbridge is approaching her last quarter at Life University ...
(Date:5/26/2016)... ... ... last week’s media reports hinting at a June rate hike after the Federal Reserve’s ... interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at Georgia ... (FOMC) dot charts are of interest to the press for their noise potential,” Dhawan ...
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. Inc ., ... with a 2016 When Work Works Award for its use of effective workplace strategies ... When Work Works project administered by the Families and Work Institute (FWI) and the ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... Chicago, Illinois (PRWEB) , ... May 26, 2016 , ... ... relationship with women’s basketball as a partner for the Tamika Catchings Legacy Tour ... , As the industry leader in hardwood basketball surfaces in all forms and levels ...
Breaking Medicine News(10 mins):